4 results
Procedural success, comprising insertion of the Stentys SDS, deployment of the Stentys Sent in the main branch, withdrawal of the Stentys SDS and creation of the Stentys Sent opening for the sidebranch, without major adverse cardiac events during…
We estimate that the anthracycline and cyclophosphamide dose could be significantly (>=15%) increased in at least 15% of ACC-treated patients. Therefore, in order to diminish the risk of under-dosing ACC, we aim to develop a neutrophil-guided…
This protocol is designed to determine the safety, tolerability, and efficacy of SGI-110 in combination with irinotecan in previously treated patients with metastatic colorectal cancer who progressed on irinotecan.
Primary Safety Objective: To describe the safety profile of 20vPnC